Gene:
NBN
nibrin

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  AT-V1; AT-V2; ATV
PharmGKB Accession Id: PA31457

Details

Cytogenetic Location: chr8 : q21.3 - q21.3
GP mRNA Boundary: chr8 : 90945564 - 90996899
GP Gene Boundary: chr8 : 90942564 - 91006899
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to NBN: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. The pharmacogenomics journal. 2010. Ho-Pun-Cheung A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inherited susceptibility to common cancers. The New England journal of medicine. 2008. Foulkes William D. PubMed

LinkOuts

Entrez Gene:
4683
OMIM:
251260
602667
UCSC Genome Browser:
NM_002485
RefSeq RNA:
NM_002485
RefSeq Protein:
NP_002476
RefSeq DNA:
AC_000051
AC_000140
NC_000008
NG_008860
NT_008046
NW_001839136
NW_923984
UniProtKB:
NBN_HUMAN (O60934)
Ensembl:
ENSG00000104320
GenAtlas:
NBN
GeneCard:
NBN
MutDB:
NBN
ALFRED:
LO029209W
HuGE:
NBN
Comparative Toxicogenomics Database:
4683
ModBase:
O60934
HumanCyc Gene:
HS02562
HGNC:
7652

Common Searches